Search

Your search keyword '"Windsor, Sheryl L."' showing total 31 results
Start Over Author "Windsor, Sheryl L." Publication Year Range Last 50 years
31 results on '"Windsor, Sheryl L."'

1. Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial

Author

Avancini Caramori, PR, Esteves Hernandes, M, Babudieri, S, Contoli, M, Fernando, M, Gonzalez Juanatey, JR, Ibañez Estellez, F, Mateos, E, Tidswell, M, Akala, O, Pursley, M, Jathavedam, A, Markley, J, Gelman, M, Ajani, Z, Mackay, F, Kunisaki, K, Martin, K, Exline, M, Huggins, J, Nicholson, L, Lim, G, Aboudara, M, Sherwin, R, Torbati, S, Wilson, J, Latorre, JG, Busch, J, Albertson, T, Matthay, M, Gandotra, S, Joseph, B, Hudock, K, Iovine, N, Quigley, J, Hyzy, R, Kutcher, M, Huang, D, Pandey, A, Sheehan, J, Solankhi, N, Rodriguez, W, Shah, B, Khanna, A, Bochicchio, G, McCarthy, M, Pan, S, Balasubraman, P, Kosiborod, Mikhail N, Windsor, Sheryl L, Vardeny, Orly, Berger, Jeffrey S, Reynolds, Harmony R, Boumakis, Stavroula, Althouse, Andrew D, Solomon, Scott D, Bhatt, Ankeet S, Peikert, Alexander, Luther, James F, Leifer, Eric S, Kindzelski, Andrei L, Cushman, Mary, Ng Gong, Michelle, Kornblith, Lucy Z, Khatri, Pooja, Kim, Keri S, Baumann Kreuziger, Lisa, Javaheri, Ali, Carpio, Carlos, Wahid, Lana, Lopez-Sendon Moreno, Jose, Alonso, Alvaro, Ho, Minh Quang, Lopez-Sendon, Jose, Lopes, Renato D, Curtis, Jeffrey L, Kirwan, Bridget-Anne, Geraci, Mark W, Neal, Matthew D, and Hochman, Judith S

Published
2024
Full Text
View/download PDF

4. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials

Author

Nassif, Michael E., Windsor, Sheryl L., Gosch, Kensey, Borlaug, Barry A., Husain, Mansoor, Inzucchi, Silvio E., Kitzman, Dalane W., McGuire, Darren K., Pitt, Bertram, Scirica, Benjamin M., Shah, Sanjiv J., Umpierrez, Guillermo, Austin, Bethany A., Lamba, Sumant, Khumri, Taiyeb, Sharma, Kavita, and Kosiborod, Mikhail N.

Published
2023
Full Text
View/download PDF

5. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Author

Nassif, Michael E., Windsor, Sheryl L., Borlaug, Barry A., Kitzman, Dalane W., Shah, Sanjiv J., Tang, Fengming, and Khariton, Yevgeniy

Subjects
Cardiac output -- Measurement, Dapagliflozin -- Testing, Cardiac patients -- Care and treatment, Heart failure -- Diagnosis -- Care and treatment -- Risk factors, Biological sciences, Health
Abstract

Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3-9.2, P = 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0-9.6, P = 0.003)) and physical limitations scores (5.3 points (95% CI 0.7-10.0, P = 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6-34.7, P = 0.007)), KCCQ-OS (4.5 points (95% CI 1.1-7.8, P = 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05-2.85, P = 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01-1.42, P = 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF. In a multicenter, randomized trial, the SGLT2 inhibitor dapagliflozin improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF), a condition for which effective treatments are lacking., Author(s): Michael E. Nassif [sup.1] [sup.2] , Sheryl L. Windsor [sup.1] , Barry A. Borlaug [sup.3] , Dalane W. Kitzman [sup.4] , Sanjiv J. Shah [sup.5] , Fengming Tang [sup.1] [...]

Published
2021
Full Text
View/download PDF

6. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Kosiborod, Mikhail N, Esterline, Russell, Furtado, Remo H M, Oscarsson, Jan, Gasparyan, Samvel B, Koch, Gary G, Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay, Buenconsejo, Joan, Langkilde, Anna Maria, Ambery, Philip, Tang, Fengming, Gosch, Kensey, Windsor, Sheryl L, Akin, Emily E, Soares, Ronaldo V P, Moia, Diogo D F, Aboudara, Matthew, Hoffmann Filho, Conrado Roberto, Feitosa, Audes D M, Fonseca, Alberto, Garla, Vishnu, Gordon, Robert A, Javaheri, Ali, Jaeger, Cristiano P, Leaes, Paulo E, Nassif, Michael, Pursley, Michael, Silveira, Fabio Serra, Barroso, Weimar Kunz Sebba, Lazcano Soto, José Roberto, Nigro Maia, Lilia, and Berwanger, Otavio

Published
2021
Full Text
View/download PDF

7. Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial

Author

Kosiborod, Mikhail N, Windsor, Sheryl L, Vardeny, Orly, Berger, Jeffrey S, Reynolds, Harmony R, Boumakis, Stavroula, Althouse, Andrew D, Solomon, Scott D, Bhatt, Ankeet S, Peikert, Alexander, Luther, James F, Leifer, Eric S, Kindzelski, Andrei L, Cushman, Mary, Ng Gong, Michelle, Kornblith, Lucy Z, Khatri, Pooja, Kim, Keri S, Baumann Kreuziger, Lisa, Javaheri, Ali, Carpio, Carlos, Wahid, Lana, Lopez-Sendon Moreno, Jose, Alonso, Alvaro, Ho, Minh Quang, Lopez-Sendon, Jose, Lopes, Renato D, Curtis, Jeffrey L, Kirwan, Bridget-Anne, Geraci, Mark W, Neal, Matthew D, Hochman, Judith S, Avancini Caramori, PR, Esteves Hernandes, M, Babudieri, S, Contoli, M, Fernando, M, Gonzalez Juanatey, JR, Ibañez Estellez, F, Mateos, E, Tidswell, M, Akala, O, Pursley, M, Jathavedam, A, Markley, J, Gelman, M, Ajani, Z, Mackay, F, Kunisaki, K, Martin, K, Exline, M, Huggins, J, Nicholson, L, Lim, G, Aboudara, M, Sherwin, R, Torbati, S, Wilson, J, Latorre, JG, Busch, J, Albertson, T, Matthay, M, Gandotra, S, Joseph, B, Hudock, K, Iovine, N, Quigley, J, Hyzy, R, Kutcher, M, Huang, D, Pandey, A, Sheehan, J, Solankhi, N, Huang, D, Rodriguez, W, Shah, B, Khanna, A, Bochicchio, G, McCarthy, M, Pan, S, and Balasubraman, P

Abstract

Patients hospitalised for COVID-19 are at risk for multiorgan failure and death. Sodium–glucose co-transporter-2 (SGLT2) inhibitors provide cardiovascular and kidney protection in patients with cardiometabolic conditions and could provide organ protection during COVID-19. We aimed to investigate whether SGLT2 inhibitors can reduce the need for organ support in patients hospitalised for COVID-19.

Published
2024
Full Text
View/download PDF

8. Association Between Change in Ambulatory Pulmonary Artery Pressures and Natriuretic Peptides in Patients with Heart Failure: Results from the EMBRACE-HF Trial.

Author

Nassif, Michael E, primary, Nguyen, Dan, additional, Spertus, John A, additional, Gosch, Kensey L., additional, Tang, Fengming, additional, Windsor, Sheryl L, additional, Jones, Philip, additional, Khariton, Yevgeniy, additional, Sauer, Andrew J., additional, and Kosiborod, Mikhail N., additional

Published
2023
Full Text
View/download PDF

9. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Author

Nassif, Michael E., Windsor, Sheryl L., Tang, Fengming, Khariton, Yevgeniy, Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Pitt, Bertram, Scirica, Benjamin M., Austin, Bethany, Drazner, Mark H., Fong, Michael W., Givertz, Michael M., Gordon, Robert A., Jermyn, Rita, Katz, Stuart D., Lamba, Sumant, Lanfear, David E., LaRue, Shane J., Lindenfeld, JoAnn, Malone, Michael, Margulies, Kenneth, Mentz, Robert J., Mutharasan, R. Kannan, Pursley, Michael, Umpierrez, Guillermo, Kosiborod, Mikhail, Malik, Ali O., Wenger, Nannette, Ogunniyi, Modele, Vellanki, Priyathama, Murphy, Brenda, Newman, Jonathan, Hartupee, Justin, Gupta, Charu, Goldsmith, Marcela, Baweja, Paramdeep, Montero, Manuel, Gottlieb, Stephen S., Costanzo, Maria Rosa, Hoang, Thanh, Warnock, Alicia, Allen, Larry, Tang, Wilson, Chen, Horng H., and Cox, John M.

Published
2019
Full Text
View/download PDF

10. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection

Author

Heerspink, Hiddo J.L., primary, Furtado, Remo H.M., additional, Berwanger, Otavio, additional, Koch, Gary G., additional, Martinez, Felipe, additional, Mukhtar, Omar, additional, Verma, Subodh, additional, Gasparyan, Samvel B., additional, Tang, Fengming, additional, Windsor, Sheryl L., additional, de Souza-Dantas, Vicente Cés, additional, del Sueldo, Mildren, additional, Frankel, Robert, additional, Javaheri, Ali, additional, Maldonado, Rafael A., additional, Morse, Caryn, additional, Mota-Gomes, Marco, additional, Shemin, Douglas, additional, Silva, Osvaldo Lourenço, additional, Tognon, Alexandre Pereira, additional, Twahirwa, Marcel, additional, Buenconsejo, Joan, additional, Esterline, Russell, additional, Oscarsson, Jan, additional, Ambery, Philip, additional, Langkilde, Anna Maria, additional, and Kosiborod, Mikhail N., additional

Published
2022
Full Text
View/download PDF

11. METABOLIC EFFECTS OF DAPAGLIFLOZIN IN HEART FAILURE ACROSS THE SPECTRUM OF EJECTION FRACTION

Author

Selvaraj, Senthil, Patel, Shachi, Sauer, Andrew, McGarrah, Robert, Jones, Philip, Kwee, Lydia, Windsor, Sheryl L., Ilkayeva, Olga, Muehlbauer, Michael, Newgard, Christopher B., Borlaug, Barry, Kitzman, Dalane W., Shah, Sanjiv Jayendra, Margulies, Kenneth B., Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Lanfear, David E., Javaheri, Ali, Umpierrez, Guillermo, Mentz, Robert John, Sharma, Kavita, Kosiborod, Mikhail, and Shah, Svati

Published
2024
Full Text
View/download PDF

12. Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure

Author

Nassif, Michael E., primary, Spertus, John A., additional, Tang, Fengming, additional, Windsor, Sheryl L., additional, Jones, Philip, additional, Thomas, Merrill, additional, Khariton, Yevgeniy, additional, Brush, John, additional, Gordon, Robert A., additional, Jermyn, Rita, additional, Jonsson, Orvar, additional, Lamba, Sumant, additional, Shavelle, David M., additional, and Kosiborod, Mikhail N., additional

Published
2021
Full Text
View/download PDF

13. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.

Author

Selvaraj, Senthil, Fu, Zhuxuan, Jones, Philip, Kwee, Lydia C., Windsor, Sheryl L., Ilkayeva, Olga, Newgard, Christopher B., Margulies, Kenneth B., Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Pitt, Bertram, Scirica, Benjamin M., Lanfear, David E., Nassif, Michael E., Javaheri, Ali, Mentz, Robert J., Kosiborod, Mikhail N., Shah, Svati H., and DEFINE-HF Investigators

Published
2022
Full Text
View/download PDF

14. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure

Author

Nassif, Michael E., primary, Qintar, Mohammed, additional, Windsor, Sheryl L., additional, Jermyn, Rita, additional, Shavelle, David M., additional, Tang, Fengming, additional, Lamba, Sumant, additional, Bhatt, Kunjan, additional, Brush, John, additional, Civitello, Andrew, additional, Gordon, Robert, additional, Jonsson, Orvar, additional, Lampert, Brent, additional, Pelzel, Jamie, additional, and Kosiborod, Mikhail N., additional

Published
2021
Full Text
View/download PDF

15. Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE‐HF trial

Author

Nassif, Michael E., primary, Windsor, Sheryl L., additional, Tang, Fengming, additional, Husain, Mansoor, additional, Inzucchi, Silvio E., additional, McGuire, Darren K., additional, Pitt, Bertram, additional, Scirica, Benjamin M., additional, Austin, Bethany, additional, Fong, Michael W., additional, LaRue, Shane J., additional, Umpierrez, Guillermo, additional, Hartupee, Justin, additional, Khariton, Yevgeniy, additional, Malik, Ali O., additional, Ogunniyi, Modele O., additional, Wenger, Nanette K., additional, and Kosiborod, Mikhail N., additional

Published
2021
Full Text
View/download PDF

17. Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial

Author

Nassif, Michael E., primary, Qintar, Mohammed, additional, Windsor, Sheryl L., additional, Jermyn, Rita, additional, Shavelle, David M., additional, Tang, Fengming, additional, Lamba, Sumant, additional, Bhatt, Kunjan, additional, Brush, John, additional, Civitello, Andrew B., additional, Gordon, Robert A., additional, Jonsson, Orvar, additional, Lampert, Brent C., additional, Pelzel, Jamie, additional, and Kosiborod, Mikhail, additional

Published
2020
Full Text
View/download PDF

20. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases

Author

Harris, William S., Lu, Gouping, Rambjor, Gro S., Walen, Ann I., Ontko, Joseph A., Cheng, Qi, and Windsor, Sheryl L.

Subjects
Omega-3 fatty acids -- Physiological aspects, Lipoprotein lipase -- Physiological aspects, Food/cooking/nutrition, Health
Abstract

The aim of these studies was to explore the possibility that enhanced triacylglycerol clearance may contribute to the hypotriacylglycerolemic effect of n -- 3 fatty acids in humans. Healthy subjects (n = 20) and hypertriacylglycerolemic patients (n = 6) were given a placebo (olive oil, OO) or a fish-oil concentrate (FOC; 41% eicosapentaenoic acid and 23% docosahexaenoic acid) in two, independent, randomized, blind trials. For the healthy subjects, the FOC treatment period was 3 wk long and FOC intakes were 5 g/d. For the patients, treatment periods were 4 wk long and dosages were 5 g [multiplied by] 70 kg body [wt.sup.-1] [multiplied by] [d.sup.-1]. Washout periods were 2-4 wk for both groups. Blood samples were drawn at the end of each phase and analyzed for plasma lipids, lipoproteins, and endogenous (nonheparin-stimulated) activities of lipoprotein lipase (LPL) and hepatic lipase (HL). In the healthy subjects the FOC decreased plasma triacylglycerol concentrations by 18% (P [is less than] 0.01), whereas in the patients concentrations were reduced by 35% (P [is less than] 0.05). Low-density-lipoprotein-cholesterol concentrations increased by 25% in the latter group (P = 0.06). FOC increased the endogenous activities of LPL and HL by 62% and 68%, respectively (P [is less than] 0.0001), in the healthy subjects, but only LPL in the patients (65%, P [is less than] 0.005). These data suggest that endogenous lipase activities may be altered by nutritional interventions, and further, that accelerated lipolysis could contribute, at least in part, to the observed effects of n -- 3 fatty acids on human lipoprotein metabolism. Am J Clin Nutr 1997;66:254-60.

Published
1997

21. n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans

Author

Harris, William S., Rambjor, Gro Siri, Windsor, Sheryl L., and Diederich, Dennis

Subjects
Omega-3 fatty acids -- Physiological aspects, Nitric oxide -- Physiological aspects, Vascular endothelium -- Physiological aspects, Food/cooking/nutrition, Health
Abstract

Fish oils rich in n - 3 fatty acids have been shown to augment endothelium-dependent vasodilation in human peripheral and coronary arteries. This suggests that n - 3 fatty acids may enhance arterial nitric oxide production. To explore this hypothesis we measured total unnary nitrate output in healthy volunteers supplemented with a fish oil concentrate (FOC; n = 15) or purified eicosapentaenoic acid (EPA, n = 14) in a placebo-controlled, parallel-group study. The FOC contained 41% EPA and 23% docosahexacnoic acid (DHA) ethyl esters, whereas EPA was 91% pure; the placebo contained olive oil ethyl esters. Doses were 5 g placebo, 5 g FOC, and 3 g EPA to keep the total n - 3 fatty acid content equal in the latter two groups. The placebo period was 2 wk long and was followed by a 3-wk n - 3 fatty acid phase. At the end of each period, 24-h urine collections and fasting blood samples were obtained. Serum and urinary nitrate concentrations were measured in a blinded fashion. The FOC produced a 43% increase in daily, creatinine-adjusted, nitrate excretion rates (P [is less than] 0.029). Because serum nitrate concentrations were not different, these findings suggest that FOC supplementation may stimulate systemic nitric oxide synthesis. The lack of effect with EPA supplementation suggests that this component of the FOC is not likely to be an active component. If confirmed, these observations suggest another mechanism whereby n - 3 fatty acids may be antiatherogenic.

Published
1997

29. Safety and Efficacy of Omacor in Severe Hypertriglyceridemia

Author

Harris, William S., Ginsberg, Henry N., Arunakul, Narin, Shachter, Neil S., Windsor, Sheryl L., Adams, Marian, Berglund, Lars, and Osmundsen, Karin

Abstract

BackgroundSevere hypertriglyceridemia is a risk factor for acute pancreatitis, therefore decreasing serum triglyceride concentrations is an important component of risk management. Omega-3 fatty acids are well known hypotriglyceridemic agents, but their efficacy in severe forms of the disorder is not well documented. Our objective was to examine the effects of Omacor, a drug composed of 85% omega-3 fatty acid ethyl esters.MethodsForty-two patients with triglyceride concentrations between 5.65 and 22.60 mmol/l (500 and 2000 mg/dl) were studied in a prospective, double-blind, placebo-controlled trial of Omacor (4 g/day for 4 months).ResultsCompared with baseline values, Omacor significantly reduced mean triglyceride concentrations by 45% (P< 0.00001), cholesterol by 15% (P< 0.001), very-low-density lipoprotein cholesterol by 32% (P< 0.0001) and cholesterol: High density lipoprotein (HDL) cholesterol ratio by 20% (P= 0.0013), and increased HDL cholesterol by 13% (P= 0.014) and low-density lipoprotein cholesterol by 31% (P= 0.0014). The placebo had no effect on these parameters. Omacor was well tolerated and no patient discontinued medication because of side effects.ConclusionsFour capsules of Omacor per day markedly decreased triglyceride concentrations in patients with severe hypertriglyceridemia. The availability of a potent and safe omega-3 fatty acid preparation for this patient population should diminish the risk for acute pancreatitis, and may also reduce the long-term risk for cardiovascular disease.

Published
1997
Full Text
View/download PDF

31. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.

Author

Selvaraj S, Patel S, Sauer AJ, McGarrah RW, Jones P, Kwee LC, Windsor SL, Ilkayeva O, Muehlbauer MJ, Newgard CB, Borlaug BA, Kitzman DW, Shah SJ, Margulies KB, Husain M, Inzucchi SE, McGuire DK, Lanfear DE, Javaheri A, Umpierrez G, Mentz RJ, Sharma K, Kosiborod MN, and Shah SH

Abstract

Background: Mechanisms of benefit with SGLT2is (sodium-glucose cotransporter-2 inhibitors) in heart failure (HF) remain incompletely characterized. Dapagliflozin alters ketone and fatty acid metabolism in HF with reduced ejection fraction though similar effects have not been observed in HF with preserved ejection fraction. We explore whether metabolic effects of SGLT2is vary across the left ventricular ejection fraction spectrum and their relationship with cardiometabolic end points in 2 randomized trials of dapagliflozin in HF., Methods: Metabolomic profiling of 61 metabolites was performed in 527 participants from DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients With HF With Reduced Ejection Fraction) and PRESERVED-HF (Dapagliflozin in PRESERVED Ejection Fraction HF; 12-week, placebo-controlled trials of dapagliflozin in HF with reduced ejection fraction and HF with preserved ejection fraction, respectively). Linear regression was used to assess changes in principal components analysis-defined metabolite factors with treatment from baseline to 12 weeks, as well as the relationship between changes in metabolite clusters and HF-related end points., Results: The mean age was 66±11 years, 43% were female, and 33% were self-identified as Black. Two principal components analysis-derived metabolite factors (which were comprised of ketone and short-/medium-chain acylcarnitines) increased with dapagliflozin compared with placebo. Ketosis (defined as 3-hydroxybutyrate >500 μM) was achieved in 4.5% with dapagliflozin versus 1.2% with placebo ( P =0.03). There were no appreciable treatment effects on amino acids, including branched-chain amino acids. Increases in several acylcarnitines were consistent across LVEF ( P interaction >0.10), whereas the ketogenic effect diminished at higher LVEF ( P interaction =0.01 for 3-hydroxybutyrate). Increases in metabolites reflecting mitochondrial dysfunction (particularly long-chain acylcarnitines) and aromatic amino acids and decreases in branched-chain amino acids were associated with worse HF-related outcomes in the overall cohort, with consistency across treatment and LVEF., Conclusions: SGLT2is demonstrate common (fatty acid) and distinct (ketogenic) metabolic signatures across the LVEF spectrum. Changes in key pathways related to fatty acid and amino acid metabolism are associated with HF-related end points and may serve as therapeutic targets across HF subtypes., Registration: URL: https://www.clinicaltrials.gov; Unique Identifiers: NCT03030235 and NCT02653482.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results